



Medical Radiation Countermeasures

MRADC

Description

Medical radiation countermeasures (MRADC) will be U.S. Food and Drug Administration (FDA)-approved products that prevent, diagnose, and treat acute radiation syndrome (ARS) caused by exposure to ionizing radiation. These countermeasures will shield and sustain the joint force over the long term and at near normal levels of effectiveness while in a contaminated environment. ARS manifests as hematopoietic (bone marrow), gastrointestinal (GI), and cerebrovascular subsyndromes depending on the dose of radiation received. Because radiation affects many organs and systems in the body, a system of multiple MRADC will be required. Future Department of Defense (DoD) increments may include diagnostic and prophylactic MRADC. The portfolio of MRADC will, when used as a system, provide a robust capability to the Warfighter.

Mission

Provide a multi-layered system of diagnostic, prophylactic and therapeutic products.

-Capability: Treat the entire spectrum of organ system-specific injuries caused by radiation exposure so that forces can maintain operational effectiveness

-Future capability: Prophylactic MRADC that is safe and easily administered, while maintaining Warfighter readiness

-Future capability: Provide real-time, accurate determination of radiation exposure levels leading to accurate triage and selection of appropriate therapy

Capabilities


- ❑ Radiological Therapeutics

Users

US Navy, US Marine Corps, US Army, US Air Force

Status

Technology Development - Anticipated Fielding: FY 2024 Q1



This Fact Sheet was cleared for public release on 1/22/2013.

Point of Contact: Chemical, Biological, Radiological, & Nuclear Information Resource Center (CBRN IRC), CBRN.IRC@us.army.mil,
Toll Free: 1-800-831-4408, Commercial: (309) 782-7349, DSN: 793-7349, Fax: (309) 782-1919